Citigroup’s Genmab GMAB Stock Holding History

Citigroup’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-100	Closed	-$3.78K	–	5628
2023 Q1	$3.78K	Buy	+100	New	+$3.84K	﹤0.01%	4999

Other funds holding GMAB

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Citigroup's GMAB Position: Q1 2026 in Review

Citigroup reduced its Genmab (GMAB) stake by 19% in Q1 2026, selling an estimated $219K and leaving 30,943 shares worth $830K. The position accounts for ﹤0.01% of the portfolio, ranked #3241.

Citigroup first reported a position in GMAB in Q3 2019 and has held it in 27 quarters since. The position peaked at $3.82M in Q4 2020. 272 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

Citigroup held 30,943 shares of Genmab worth $830K as of Q1 2026.
Citigroup sold 7,296 Genmab shares in Q1 2026, an estimated $219K.
Genmab made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3241 holding.
Citigroup first reported a position in Genmab in Q3 2019 and has held it in 27 quarters since.
Citigroup's Genmab position peaked at $3.82M in Q4 2020.
272 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.